Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4291)	3/9/1998 10:00:00 PM
From: Pseudo Biologist	Respond to of 9719

Peter, thanks a lot. I have to run, but will examine this information more carefully. In the mean time, and for those interested in DNA vaccines, here is a link to a clinician-oriented article: nejm.org The NEJM's Molecular Medicine series, also accessible from the above link, is useful to figure out how (and when?) new developments in molecular biology, genomics, and the like may translate into practical medical applications. PB

To: Biomaven who wrote (4291)	3/10/1998 11:14:00 AM
From: squetch	Respond to of 9719

Peter & PB, PCYC is still an early stage company. I think this ASCO will put them on the map big time. That is my understanding of where the final PII Gd-Tex data will be presented. In the May 97 release for interim data on a PIb/II for 14 fourteen patients evaluated, 2 Complete responders and 9 partial responders, a 78% response rate, in brain cancer which had metastasized primarily from breast and lung cancer. What would 4 CR and 12 PR do for recognition?(just a hoped for lowball guess. I have another hope, but it has me in fear of the nice men in white suits coming to tell me it is nap time) They also have released data before the start of the PII where high dosage group survival was >363 days vs low dosage survival of 66 days. >>we don't know that it is 100% safe<<Agreed and I'm sure it won't be 100%.(:>) Grade 3 and 4 abnormalities in liver fx which have been seen late in the 10-day course of Gd-Tex therapy. It hadn't prevented any of the patients from completing therapy. We shall know more w/ the max tolerated dosage data in May. Cowen has PCYC earning $6.85 in '02. squetch